Freeslate Releases LEA 8.5 Software for Designing, Executing, and Reporting on High Throughput Experiments - FOX 54 WZDX – Huntsville News, Weather and Sports

Freeslate Releases LEA 8.5 Software for Designing, Executing, and Reporting on High Throughput Experiments

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

Latest Version of Lab Execution and Analysis (LEA) Software Improves the Robustness and Productivity of Lab Automation Systems

Sunnyvale, CA (PRWEB) June 26, 2014

Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced the release of LEA 8.5. Freeslate LEA software is the leading software suite for supporting the design, execution, and analysis of high throughput experiments. LEA integrates the entire experimental process, from intuitive design of experiments through execution on Freeslate lab automation systems to the collection, analysis, and presentation of data. The latest version, LEA 8.5, improves the efficiency and robustness of experiment execution with Freeslate lab automation systems.

  •     An intuitive, simple Auto-Adapt feature reduces system training time by over 90 percent while ensuring consistent, accurate alignment by even novice users.
  •     The new Intelligent Feedback feature ensures even more robust and predictable liquid dispensing and handling of vials and plates.
  •     The new Look Ahead feature significantly improves the speed and efficiency of liquid dispensing.

We are very excited to release this next version of our software. LEA 8.5 is targeted at improving our customers ability to get the best productivity from their research and get maximum value from their investment in our systems, said John S. Senaldi, President and CEO of Freeslate. This release is one more example of our long-term commitment to develop outstanding software that, when combined with our lab automation systems, ultimately translates to smarter, faster, and more efficient research.

All Freeslate systems, including the powerful Core Module 3 (CM3) and user friendly CM Protégé, are driven by Freeslate LEA software. Within Freeslate LEA software suite, Library Studio® allows scientists to design high throughput experiments for a variety of applications, including process chemistry, pharmaceutical API salt selection and crystallization, and biologics formulation. Automation Studio, a second module, automates and controls Freeslate automation systems and third party instruments to create a fully integrated automation workflow. Overall, Freeslate LEA software suite handles experiment design, data collection and storage, real-time data processing, data analysis, searching, and reporting all within a single, easy-to-use environment. This allows users to design experiments quickly using its logical, recipe-oriented approach, and link sample composition and experimental conditions to analytical data in a searchable database for easy viewing and reporting.

About Freeslate

Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customers bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/06/prweb11975449.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Powered by WorldNow